

**Effect of Iron- and Zinc-Biofortified Pearl Millet Consumption on Growth and
Immune Competence in Children Aged 12-18 Months in India—Study Protocol
for a Randomised Controlled Trial**

Clinical Trials ID: NCT02233764

September 6, 2017

Effect of Iron- and Zinc-Biofortified Pearl Millet Consumption on Growth and Immune Competence in Children Aged 12-18 Months in India—Study Protocol for a Randomised Controlled Trial

Saurabh Mehta^{1,2}, Julia L. Finkelstein^{1,3}, Sudha Venkatramanan¹, Samantha L. Huey¹, Shobha A. Udipi⁴, Padmini Ghugre⁵, Caleb Ruth⁶, Richard L. Canfield¹, Anura V. Kurpad³, Ramesh D. Potdar⁷, Jere D. Haas¹

¹Division of Nutritional Sciences, Cornell University, Ithaca, New York, US

²Institute for Nutritional Sciences, Global Health, and Technology, Cornell University, Ithaca, New York, US

³St. John's Research Institute, Bangalore, India (SJRI)

⁴Kasturba Health Society Medical Research Centre (KHS-MRC), Mumbai, India

⁵Shreemati Nathibai Damodar Thackersey, Women's University (SNDT), Mumbai, India

⁶ Data Performance LLC, Ithaca, New York, US

⁷Center for the Study of Social Change, Mumbai, India (CSSC)

Corresponding Author (Principal Investigator):

Saurabh Mehta, MBBS, ScD

314 Savage Hall, Ithaca, New York 14853, US

Phone: +1-607-255-2640; Fax: +1-607-255-1033

E-mail: smehta@cornell.edu

Tables and Figures: 2

Keywords: Biofortification, iron, zinc, pearl millet, children, growth

ABSTRACT

Introduction: Biofortified crops represent a sustainable agricultural solution for the widespread micronutrient malnutrition in India and other resource-limited settings. This study aims to investigate the effect of the consumption of iron and zinc-biofortified pearl millet by children on biomarkers of iron and zinc status and growth outcomes. Additionally, we will assess immune function in the participants.

Methods and Analysis: We will conduct a randomised controlled feeding trial in identified slums of Mumbai, India among 250 children between 12-18 months of age for 9 months. Children will be randomised to receive the biofortified pearl millet (FeZn-PM, ICTP8203-Fe) or non-biofortified pearl millet. Anthropometric and morbidity data will be gathered every month for 9 months. Biological samples will be collected at baseline, midline, and endline, to assess iron and zinc status, including haemoglobin, serum ferritin, serum transferrin receptor, serum zinc, C-reactive protein, and alpha-1 acid glycoprotein. Biological samples will be archived for future analyses. The midline measurement will be a random serial sample between baseline and endline. Immune function will be assessed at each time point by the measurement of T cell counts in a subset, respectively.

Ethics and Dissemination: This study has obtained clearance from the Health Ministry Screening Committee (HMSC) of the Indian Council of Medical Research (ICMR). Ethical clearance has been obtained from Cornell University's Institutional Review Board, the Inter System Biomedica Ethics Committee (ISBEC), and St. John's Research Institute Institutional Ethics Review Board. The results of this study

1 will be disseminated at several research conferences and as published articles in
2 peer-reviewed journals.

3

4 **Registration Details:** Clinicaltrials.gov registration number: NCT02233764
5 (registered on September 4, 2014). Clinical Trials Registry of India (CTRI), reference
6 number REF/2014/10/007731, CTRI number CTRI/2015/11/006376.

7

Strengths and limitations of this study

- This is the first longitudinal randomised controlled trial to determine the efficacy of consuming complementary foods prepared using iron- and zinc-biofortified pearl millet on both nutritional status and functional outcomes, among children 12-18 months of age.
- The longitudinal random midline serial sampling strategy both increases sensitivity and the power of the proposed study, while reducing cost and invasiveness (by decreasing the number of biological samples from each participant).
- Data will be collected on iPads or laptops, using a mobile electronic data capture system framework on the iOS platform. This will decrease the potential for error in data entry compared to standard written hard copies of forms, and allow direct uploading of data using a secure server.
- One limitation of this study is that blinding may not be possible due to potential sensory differences between the crops used in the two arms of the study.

1 INTRODUCTION

2 The burden of iron and zinc deficiency

3 Deficiencies in iron and zinc are two of the most important public health problems
4 globally^{1 2}. The role of iron deficiency in growth and development of children has
5 been demonstrated in several studies³⁻⁵. Similarly, it appears that a major fraction of
6 stunting can be explained by zinc deficiency⁶. Suboptimal iron and zinc status also
7 impairs immune functioning through a number of mechanisms, including a reduction
8 in the proportion of circulating T-lymphocytes and lymphocyte proliferative
9 responses⁷. Cognitive deficits are also observed with iron and zinc deficiency,
10 including irreversible impairments in neurological and psychomotor development of
11 children⁸.

13 Iron and zinc biofortification

14 Biofortification has the potential to be a more sustainable and cost-effective
15 approach compared to other strategies such as diet diversification, fortification, and
16 supplementation, to address micronutrient malnutrition among vulnerable
17 populations⁹. In India, staple crops such as pearl millet (*Pennisetum glaucum*) are
18 consumed as part of the daily diet, particularly in Maharashtra, Gujarat, Rajasthan,
19 and Karnataka. The iron and zinc concentration in biofortified PM is reported to be
20 70-85 and 35-40 parts per million (ppm), respectively¹⁰. Previous research from
21 southern India and preliminary data from our acceptability study indicate that the
22 mean consumption of pearl millet (PM) flour in children is 61-80 g/day among Indian
23 children^{11 12}, showing the suitability of this crop as a target for biofortification. Thus,
24 for children, iron and zinc intakes from PM would be 7-8 mg/100g and 3-4 mg/100g,
25 respectively¹⁰, and would help meet 50 to 70% of the recommended dietary

allowances (RDA) for children between 1-3 years of age. These estimates are based on the RDA recently recommended for Indians by the Indian Council of Medical Research¹³.

The primary objectives of this randomised controlled trial are to study the effect of the daily consumption of high iron- and zinc-biofortified pearl millet on biomarkers of iron and zinc status, as defined by haemoglobin, serum ferritin, serum transferrin receptor, serum zinc, and C-reactive protein; and growth, as defined by length-for-age, weight-for-age and weight-for-length, among 12-18-month-old children, as compared to children receiving conventional pearl millet. Additionally, we will assess the effect of high iron- and zinc-biofortified pearl millet by 12-18-month-old children on immune outcomes.

METHODS AND ANALYSIS

Study setting

This study will take place in identified slums of urban Mumbai, Maharashtra, India. Mumbai is the commercial capital of India, and about 41.3% of city's populace resides in urban slums¹⁴.

Study design

We will conduct a randomised controlled trial in which children (12 to 18 months old) will be fed complementary foods prepared using iron- and zinc-biofortified pearl millet (FeZn-PM) or the comparator conventional pearl millet for nine months. Caregivers will be requested to provide three (3) informed consent forms for 1) census; 2) screening; and 3) enrolment into the trial. Caregivers who provide all

three consents are considered eligible to be screened. Details of the informed consent process can be found the section “Informed consent process.”

1. Census: Before the study begins, a census will be conducted in the identified slums to gather information on the age of the child, sex, and location.

2. Screening: Consent will be obtained for screening and inclusion in the trial. Non-invasive data will be collected on: dietary allergies, use of iron or zinc dietary supplements, availability of a caregiver, and if the caregivers are planning to stay in the slum for the duration of the study. Anthropometry and dietary intake will also be measured. If the children were not dewormed recently, they will be provided liquid albendazole by the study physician at the study clinic (5 mL of syrup equivalent to 200 mg per dose). If still eligible for the study, blood will be collected to measure complete blood counts including haemoglobin for further determination of eligibility.

3. Randomization: A statistician from the Cornell Statistical Consulting Unit will generate the random allocation sequence using a statistical software package (SAS version 9.4); the randomization sequence key will be blinded to all study personnel except the study statistician and the Filemaker database developer until follow-up is over. Randomization will be allocated at the individual level. Individuals will be randomized in blocks of 60. Pearl millet food products will coded by study arm (Arm 1: iron- and zinc-biofortified pearl millet; Arm 2: conventional pearl millet). Children will be randomized to either study arm and will be monitored to ascertain they consume the assigned food product throughout the study duration. The midline measurement (including biological sample collection) will be a random serial sample

taken at any month (months 2-7) between the baseline and endline measurements¹⁵. Longitudinal midline random serial sampling is often used in population pharmacokinetic research and has been shown to be a useful strategy for iron fortification efficacy studies, by describing the pattern of iron repletion¹⁵.

Intervention and comparator

The intervention is iron-and-zinc-biofortified pearl millet (ICTP-8203) developed by the International Crops Research Institute for the Semi-Arid Tropics (ICRISAT), and the comparator is a conventional pearl millet that is commercially available on the market. The comparator was chosen because it is similar to the intervention in all aspects, except for iron and zinc content, which allows direct analysis of the impact of the iron-and-zinc-biofortified variety on our outcome measurements. The nutrient composition of biofortified and the conventional pearl millet flour are presented in Table 1. We expect a child to consume an average of 60 g of pearl millet per day, depending on the age of the child¹¹.

Table 1: Nutrient composition of pearl millet varieties		
	Biofortified (per 100 g flour)	Control (per 100 g flour)
Moisture (g)	6.89	7.16
Fat (g)	7.88	8.74
Protein (g)	13.46	13.46
Carbohydrate (g)	30.22	30.98
Energy (Kcal)	246	256
Ash (g)	1.99	1.63
Phytate (mg)	876.59	998.44
Iron (mg)	6.64	2.56
Zinc (mg)	4.43	1.24

1 Inclusion and exclusion criteria

2 Inclusion criteria

3 Participants included in this study will be 12-18-month-old male and female children
4 with haemoglobin concentration greater than or equal to 9 g/dL, living in urban slums
5 of Mumbai.

6 Exclusion criteria

7 Children will be excluded if: (1) they are younger than 12 months, 0 days old or older
8 than 18 months, 30 days at enrolment; (2) their haemoglobin concentration is less
9 than 9 g/dL or haemoglobinopathy is present (as indicated via abnormal peak via
10 hemoglobin variant analysis and confirmed by CSSC physicians); (3) they show
11 signs of severe malnutrition (a weight-for-length -3)¹⁶; (4) their caregiver reports prior
12 known diagnosis of HIV, tuberculosis, or current diagnoses of HIV, malaria,
13 tuberculosis, and/or dengue fever; (5) their caregiver is unavailable to bring the child
14 to the feeding centre during follow-up; (6) the child has any known dietary allergies;
15 and (7) their caregivers will leave the study site for greater than 4 weeks during the
16 follow-up period; (8) prior (within the past one year) or current consumption of iron or
17 zinc supplements. Children who are severely anemic will be referred to physicians
18 at the Center for the Study of Social Change (CSSC).

19

20 Informed consent process

21 Research assistants will obtain informed consent from caregivers. Three consent
22 forms will be collected at the Screening Visit: 1) Pre-Screening Consent (non-
23 invasive questionnaires to determine age eligibility, use of dietary supplements,
24 availability of caregiver, etc. as described in Exclusion Criteria above; 2) Screening
25 Consent (invasive procedures including blood collection and anthropometric

measurements to assess malnutrition); and 3) Intervention Consent (including baseline procedures such as a full doctor's exam and detailed background questionnaires).

Feeding Centre

Feeding centres will be located near to where children and their caregivers' dwellings are clustered, to ensure that travel time from their home to the feeding centre is within walking distance.

Sample size estimation

Our estimates of sample size are based on assumptions about mean values and associated variation in haemoglobin and serum ferritin. We expect 50–75% of these children to have iron and zinc deficiency based on published literature¹⁷ and preliminary results (unpublished). We assume that absorbed iron will be transferred to body stores in the liver, and that the change in liver stores is reflected in changes in serum ferritin at a rate of 8 µg/L of serum ferritin per mg liver iron in non-anaemic, iron-depleted children. Iron-deficient, anaemic (haemoglobin < 11 g/dL¹⁸) children will have their absorbable iron directed to haemoglobin synthesis in the early months of the feeding trial. We estimate that the children consuming biofortified FeZn-PM will demonstrate a gain of 1 g/dL in haemoglobin concentrations in 2.4 months, whereas children consuming control pearl millet will need more than 9 months to demonstrate the same increase. To detect a significant increase in ferritin from the baseline value of 1.79 (6 mg/L) with standard deviation of 1.2, in the experimental group, compared to the control group, at a power of 80% and 5% significance level, 96 participants will be required.

Follow-up

Assessments

At baseline, we will assess anthropometry; collect blood for analysis of hemoglobin, iron, zinc, CRP, and AGP biomarkers in the blood (all blood analyses other than complete blood counts and T cell counts will be stored at -80 and then performed in batch at the end of the trial); nutrient intake measures using multiple-pass 24-h dietary recall¹⁹ for children and mothers; socio-economic and demographic information; and morbidity history. Follow-up will continue for 9 months and will include monthly anthropometric measurements, morbidity assessments, Infant and Young Child Feeding Questionnaire²⁰, and 24-hour dietary recall¹⁹. Both maternal and infant dietary data will be collected via paper forms and entered into the CS Dietary System Rel. 1.10, to calculate energy and nutrient intakes. Additionally, we will collect rectal swab or stool samples to determine microbiome composition in potential future ancillary analyses. The midline time point will be a random serial sample that occurs between the baseline and endline measures. Children may visit the CSSC clinic at any time during the trial for healthcare treatment. All blood collection procedures will include the use a local anaesthetic (Prilox- Lidocaine and Prilocaine cream) to decrease pain, and a Vein Finder device to illuminate the veins to better identify the injection site.

Administration of intervention

Both arms will receive complementary foods prepared with pearl millet three times per day, 6 days per week, for 9 months. Culturally acceptable pearl millet based complementary foods were developed by SNTD University and the acceptability of

these food products was tested on the caregivers and the children from the slums of Mumbai¹⁰. We will conduct a run-in/pilot phase of the study with 1-3 selected feeding centres.

Each day, the child's caregiver will bring the child to their feeding centre. Two meals will be consumed at the feeding centre; the third meal may be consumed at home.

The food intake of the two meals at the feeding centre will be measured directly before and after consumption. To measure the intake of the third meal, the weight of unconsumed food from the third meal will be measured the next morning at the feeding centre. To assure adherence, healthcare workers will follow up with the participants' caregivers and record reasons for non-adherence. Throughout the study, we will conduct periodic analysis of random samples of both grain varieties and prepared food products to ensure food safety and quality of the intervention.

Primary outcome measurements

Biomarkers of iron and zinc status

We will determine if biofortified pearl millet improves iron and zinc status compared to children who consume non-biofortified pearl millet. Specifically, iron and zinc status will be assessed by measuring concentrations of haemoglobin (Hb), serum ferritin, serum transferrin receptor (sTfR) and plasma zinc at enrolment (baseline), midline, and endline. Additionally, we will measure concentrations of inflammatory biomarkers C-reactive protein (CRP) and alpha 1-acid glycoprotein (AGP), as iron and zinc biomarkers can be influenced by inflammation.

Growth

We will assess change in a child's growth as another outcome variable to determine if iron-biofortified pearl millet reduces the risk of underweight (weight-for-age z score < -2), wasting (weight-for-height z-score < -2) and stunting (length-for-age z score < -2) during the 9-month intervention period, compared to those who receive non-biofortified pearl millet. We will measure weight (kg) and length (cm) at baseline and monthly throughout follow-up. The weight and length data will be converted to weight-for-age, weight-for-length z-score, and length-for-age z-score. The growth rates (as kg/month, and cm/month) will also be compared from the absolute measurements after controlling for age.

Additional outcomes

Immune function

We will assess immune function by measuring T cell counts and vaccine responses. Additionally, we will collect morbidity data, including changes in types and frequencies of morbidities such as diarrhoeal illness, pneumonia, and any chronic disease throughout follow-up during each clinic visit. Caregivers will also be encouraged to come to the clinic at any time for any health-related reasons, which will also be recorded. This will provide an accurate representation of both innate and adaptive immunity in participants.

Cognitive function

To determine if consumption of biofortified pearl millet improves child cognitive function, compared to consumption of non-biofortified pearl millet, we will assess in a subset of children aspects of cognition that (1) previously have been shown to be sensitive to the effects of early iron and/or zinc deficiency, or (2) draw heavily upon

1 brain structures or processes thought to be vulnerable to early iron and/or zinc
2 deficiency, based on studies of animal models and humans. Thus, we will assess
3 multiple specific aspects of memory, attention and processing speed using
4 automated eye trackers²¹. In addition, we will also assess higher-level, integrative
5 cognitive abilities, including problem-solving and exploratory behavior and global
6 aspects of attention and inattention during free play with toys²².

7 **Data collection and storage**

9 Prior to data collection, the field staff will be trained on ethical and data collection
10 procedures. The protocol of data collection forms to be used is shown in Figure 1. All
11 data except dietary data will be collected on iPads or laptops for the proposed
12 project. We will use a mobile electronic data capture (mEDC) framework on the iOS
13 platform, *Connedct*, specifically designed for this project²³. A secure server will be
14 utilized for uploading, storing, and accessing the data. This will enable real-time
15 feedback and error checking, as well as eliminate errors associated with data entry,
16 facilitating faster data analysis and rapid dissemination of results. All information will
17 be kept confidential. All names will be removed from the data for analysis. The
18 identifying codes and linked names will be securely stored in password-protected
19 computers. All data will be securely stored on a third-party server, which will have
20 limited access by study team members. All biological specimens will be collected by
21 trained medical professionals and evaluated by certified laboratories within India.
22 Biological specimens will be stored appropriately throughout the duration of the
23 study and after the study for future analysis.

24 **Data analysis**

We will use an intention-to-treat approach to determine the effect of biofortified pearl millet on the outcomes described above. Advanced analysis will use mixed models to account for pearl millet-based complementary foods consumed and use each block of 60 as a random effect. We will also plot dose-response curves using restricted cubic splines that will help us detect any threshold effects, as well as non-linear associations. Nonparametric tests, such as the Hodges-Lehmann test, will be used where relevant, as in the case of non-normally distributed variables including serum ferritin.

Study monitoring board

A Data Safety Monitoring Board (DSMB) will be established for this study and will include experts representing Cornell University and SNDT University who are not directly involved in the trial. The DSMB members will oversee the study and will periodically monitor the progress and outcomes of the intervention.

Reporting of adverse events

All adverse events will be reported by the study physician via an Adverse Event/Serious Adverse Event Report (AE/SAE) form. When an adverse event occurs, study physicians, research assistants and/or other study personnel will undertake all necessary precautions to ensure the safety and well-being of the participant.

The following study protocol endpoints will be considered to define safety and efficacy outcomes, and establish un-blinding and stopping guidelines in this trial, as per the discretion of the DSMB: 1. Diagnosis of the development of severe acute

malnutrition such as Kwashiorkor; 2. Occurrence of all-cause death. Demonstration of efficacy, namely a significant beneficial effect on mortality and other adverse outcomes will be used as a guideline to determine if the study should be un-blinded, stopped, or terminated.

ETHICS AND DISSEMINATION

Before conducting interviews or allowing participation in the study, written informed consent will be obtained from each participant's guardians/primary caregivers, and research assistants will record each granting of informed consent using audio and video technology. Severely anaemic (<7 g/dL) and malnourished children will be provided with appropriate medical care and referred to CSSC. The caregivers will be assured of the confidentiality and anonymity of reports and publications generated from this study. Participation will be voluntary, and participants will be assured that refusal to participate in the study will not impact their access to care. The ethical clearance for this study has been obtained from the Institutional Review Board of Cornell University; Intersystem Biomedical Ethics Committee (ISBEC) of SNDT University, Mumbai, India; and the Institutional Review Board of St. John's Research Institute, Bangalore, India. This study has received clearance from Health Ministry's Screening Committee (HMSC) of the ICMR. The results of this study will be disseminated at several research conferences and as published articles in peer-reviewed journals. The present study protocol was prepared in accordance to the SPIRIT statement²⁴. This trial has been registered at Clinicaltrials.gov (registration number NCT02233764) and the Clinical Trials Registry of India (CTRI) (reference number REF/2014/10/007731, CTRI number CTRI/2015/11/006376).

REFERENCES

1. Black MM, Quigg AM, Hurley KM, et al. Iron deficiency and iron-deficiency anemia in the first two years of life: strategies to prevent loss of developmental potential. *Nutrition reviews* 2011;69 Suppl 1:S64-70. doi: 10.1111/j.1753-4887.2011.00435.x
2. Black RE, Victora CG, Walker SP, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. *The Lancet* 2013;382(9890):427-51. doi: 10.1016/s0140-6736(13)60937-x
3. Vucic V, Berti C, Vollhardt C, et al. Effect of iron intervention on growth during gestation, infancy, childhood, and adolescence: a systematic review with meta-analysis. *Nutrition reviews* 2013;71(6):386-401. doi: 10.1111/nure.12037
4. Lawless J, Latham M, Kinoti S, et al. Iron Supplementation Improves Appetite and Growth in Anemic Kenyan Primary School Children. *Journal of Nutrition* 1994;124:645-54.
5. Kanani S, RH P. Symposium Supplementation with Iron and Folic Acid Enhances Growth in Adolescent Indian Girls. *Journal of Nutrition* 2000;130(452S-455S)
6. Cole CR, Lifshitz F. Zinc nutrition and growth retardation. *Pediatr Endocrinol Rev* 2008;5(4):889-96.
7. Walter T, Olivares M, Pizarro F, et al. Iron, anemia, and infection. *Nutrition reviews* 1997;55(4):111-24.
8. Georgieff MK. Long-term brain and behavioral consequences of early iron deficiency. *Nutrition reviews* 2011;69 Suppl 1:S43-8. doi: 10.1111/j.1753-4887.2011.00432.x
9. HE B. Plant Breeding- A New Tool for Fighting Micronutrient Malnutrition. *Am Soc Nutr Sci* 2002:511-3.
10. Huey SL, Venkatramanan S, Udipi SA, et al. Acceptability of Iron- and Zinc-Biofortified Pearl Millet (ICTP-8203)-based Complementary Foods Among Children in an Urban Slum of Mumbai, India. *Frontiers in Nutrition* 2017;4(August 2017, Article 39):1-10. doi: 10.3389/fnut.2017.00039
11. Acceptability of iron biofortified pearl millet among young children in urban slums of Mumbai, India. *Experimental Biology*; 2016; San Diego. FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
12. Kodkany BS, Bellad RM, Mahantshetti NS, et al. Biofortification of pearl millet with iron and zinc in a randomized controlled trial increases absorption of these minerals above physiologic requirements in young children. *The Journal of nutrition* 2013;143(9):1489-93. doi: 10.3945/jn.113.176677
13. I.C.M.R. Nutrient Requirements and Recommended Dietary Allowances for Indians. In: Research EGotlCoM, ed. Hyderabad, India: National Institute of Nutrition, Indian Council of Medical Research, 2009.
14. Chandramouli C. HOUSING STOCK, AMENITIES & ASSETS IN SLUMS - CENSUS 2011 (Presentation). In: Affairs MoH, ed. India: Census of India, 2011.

- 1 15. Andersson M, Theis W, Zimmermann MB, et al. Random serial sampling to
2 evaluate efficacy of iron fortification: a randomized controlled trial of
3 margarine fortification with ferric pyrophosphate or sodium iron edetate. *The*
4 *American journal of clinical nutrition* 2010;92(5):1094-104. doi:
5 10.3945/ajcn.2010.29523
- 6 16. de Onis M, Onyango A, Borghi E, et al. Worldwide implementation of the WHO
7 Child Growth Standards. *Public health nutrition* 2012;15(9):1603-10. doi:
8 10.1017/S136898001200105X
- 9 17. Kapoor D, Agarwal KN, Sharma S, et al. Iron status of children aged 9-36
10 months in an urban slum Integrated Child Development Services project in
11 Delhi. *Indian Pediatr* 2002;39(2):136-44.
- 12 18. WHO/NMH/NHD/11.1. Haemoglobin concentrations for the diagnosis of anaemia
13 and assessment of severity. 2011
- 14 19. Rizek RL, Pao EM. Dietary intake methodology I. USDA surveys and supporting
15 research. *The Journal of nutrition* 1990;120 Suppl 11:1525-9.
- 16 20. Organization WH. Indicators for assessing infant and young child feeding
17 practices, 2008.
- 18 21. Aslin R, B M. Automated Corneal-Reflection Eye Tracking in Infancy-
19 Methodological Developments and Applications to Cognition. *Infancy*
20 2004;6:155-63. doi: 10.1207/s15327078in0602_1
- 21 22. Ruff HA, Lawson KR, Parrinello R, et al. Long-term stability of individual
22 differences in sustained attention in the early years. *Child Dev* 1990;61(1):60-
23 75.
- 24 23. Ruth C, Yu EA, Huey SL, et al. ConnEDCt: A Development Framework for
25 Mobile Electronic Data Capture in Disconnected Communities. *Computer*
26 *Science and Education in Computer Science* 2016;12:219-33.
- 27 24. Chan A-W, Tetzlaff J, Altman D, et al. SPIRIT 2013 Statement- Defining
28 Standard Protocol Items for Clinical Trials. *Ann Intern Med* 2013;158:200-7.

30 **AUTHORS' CONTRIBUTIONS:** Saurabh Mehta, Julia L. Finkelstein and Jere D.

31 Haas designed the study, conceived the research questions and prepared the study
32 protocol. Saurabh Mehta is the principal investigator of the study and Julia L.

33 Finkelstein, Jere D. Haas, Shobha A. Udipi, Padmini Ghugre, Richard L. Canfield,

34 Anura V. Kurpad, and Ramesh D. Potdar are co-investigators. Caleb Ruth

35 developed the database used in this trial and provided feedback on the protocol.

36 Samantha L. Huey and Sudha Venkatramanan contributed to the editing of the

37 protocol and will supervise the data collection under the guidance of the

38 investigators. All authors read and approved the final protocol.

ABBREVIATIONS: AGP: Alpha 1-acid glycoprotein; CRP: C-reactive protein; Fe: Iron; FeZn-PM: iron- and zinc-enhanced variety of pearl millet; ICRISAT: International Crops Research Institute for the Semi-Arid Tropics; ICTP8203-Fe: high iron and zinc-biofortified pearl millet variety; ICMR: Indian Council of Medical Research; ISBEC: Intersystem Biomedical Ethics Committee; IRB: Institutional Review Board; KHS: Kasturba Health Society; PM: Pearl Millet; RDA: Recommended Daily Allowance; SJRI: St. John's Research Institute; SNTD: Shreemati Nathibai Damodar Thackersey; sTfR: Serum transferrin receptor; Zn: Zinc

FUNDING: This work was supported by HarvestPlus, grant number 2014H8302.

Address:

HarvestPlus

2033 K St NW

Washington, DC 20006

CONFLICTS OF INTEREST: SM is an unpaid board member for a diagnostic start up focused on developing point-of-care assays for nutritional status informed by his research as a faculty member at Cornell University. All other authors report no conflict of interest.

Figure Legends:

Figure 1. Form collection protocol.